Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 plus Opdivo with mFOLFOX6 and bevacizumab vs standard of care in first-line PD-L1 positive advanced colorectal cancer
jRCT2051250119Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ONO-4578 and nivolumab in colorectal cancer (CRC) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and Objective Response Rate. Started Dec 2025; status: recruiting.
02
Drugs
ONO-4578nivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2051250119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250119.